ARRDC4

Across TCGA pan-cancer cohorts, ARRDC4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ARRDC4 data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARRDC4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ARRDC4 expression acts as an unfavorable survival marker, although some lineages such as LUAD show a favorable association.

PDAC, UCEC, and LUAD are the cancer types where ARRDC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.488	0.899	.007	9	view →
UCEC	DFS	Quartile	All	0.778	0.963	.011	8	view →
LUAD	OS	Quartile	All	0.937	0.682	.030	3	view →
CCRCC	OS	Median	All	0.766	0.952	.026	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ARRDC4–PDAC (DFS)

Open the PDAC breakdown →